IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/799529 Confirmation No.: 8501

Applicant : Carl Podella
Filing Date : March 11, 2004

Title : ALTERING METABOLISM IN BIOLOGICAL PROCESSES

Group Art Unit : 1636

Examiner : Akhavan, Ramin

Docket No. : 700145.4004

Customer No. : 34313

Commissioner for Patents Mail Stop Amendment PO Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 CFR §§ 1.97 and 1.98, the items identified in this information Disclosure Statement ("IDS") are brought to the attention of the Office. The items are listed on the attached form PTO/SB/08a (PTO-1449). In accordance with the USPTO waiver of the requirement under 37 CFR 1.98(a)(2)(i), only copies of foreign patent documents and non-patent literature are enclosed for the convenience of the Examiner.

The items identified in this IDS may or may not be "material" pursuant to 37 CFR § 1.56. The submission thereof by Applicant is not to be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR § 1.97(h)), or even qualifies as "prior art" under 35 USC § 102 with respect to this invention unless specifically designated by Applicant as such.

 Applicant
 :
 Podella

 Appl. No.
 :
 107799529

 Examiner
 :
 Akhavan, Ramin

 Docket No.
 :
 700145.4004

INFORMATION DISCLOSURE STATEMENT FILING PROVISION:

\boxtimes	This ID	OS is believed to be timely in that it is being submitted under 37 CFR § 1.97(b),
that is	(1) with	in three months of the filing date of the application, which is not a continued
prosec	ution a	pplication filed under § 1.53(d); or (2) within three months of entry of the national
stage :	as set f	orth in 37 CFR § 1.491; or (3) before the mailing of a first Office action on the
merits	or (4)	before the mailing of a first Office action after filing a request for continued
examiı	nation u	inder § 1.114. Thus, no fee is required.
		However, if the undersigned is in error in this regard, Applicant respectfully
		requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if
		applicable, and charge the fee due under 37 CFR §1.17(p) to the deposit
		account referenced below.
		However, if the undersigned is in error in this regard, Applicant respectfully
		requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if
		applicable, and a statement under 37 CFR § 1.97(e) is included below, thus
		no fee is required.
	This ID	OS is being submitted under 37 CFR § 1.97(c), that is after mailing of a first Office
action	on the	merits, but before a Final Action under 37 CFR § 1.113 or a Notice of Allowance
under	37 CFF	₹ § 1.311.
		The fee due under 37 CFR § 1.17(p) is submitted herewith.
		A statement under 37 CFR § 1.97(e) is included below, thus no fee is
		required. In the event that this IDS is not received before a Final Action or a
		Notice of Allowance, then Applicant respectfully requests that the Office
		consider the filing of these papers to be submitted under 37 CFR § 1.97(d)
		and charge the fee due under 37 CFR § 1.17(p) to the deposit account below.
	This IE	OS is being submitted under 37 CFR § 1.97(d), that is after a Final Action under 37
CFR §	1.113	or a Notice of Allowance under 37 CFR § 1.311, but before payment of the issue
fee. A	statem	ent under 37 CFR § 1.97(e) is included below. The fee due under 37 CFR
§ 1.17	(p) is si	ubmitted herewith.

 Applicant
 :
 Podella

 Appl. No.
 :
 10/799529

 Examiner
 :
 Akhavan, Ramin

 Docket No.
 :
 700145.4004

	STATEMENT UNDER	37 CF	R § 1.97(e):		
	Each item contained in this IDS was first cited in any communication from a foreign				
paten	t office in a counterpart foreign application	not m	ore than three months prior to the filing o		
this II	os.				
	No item contained in this IDS was cited in	n a co	mmunication from a foreign patent office		
inac	ounterpart foreign application, and, to the	cnowle	edge of the person signing this statement		
	making reasonable inquiry, no item of infor				
indivi	dual designated in 37 CFR § 1.56(c) more	than t	hree months prior to the filing of this IDS.		
	PAYMENT AND/OR AUTHOR	IZATIO	N TO CHARGE FEES;		
	Please charge to Deposit Account No. 1	5-066	5 for the above fee(s).		
\boxtimes	The Commissioner is authorized to charg	je any	fees required by the filing of these		
pape	rs, and to credit any overpayment to Orrick	, Herr	ngton & Sutcliffe's Deposit Account		
No. 1	5-0665.				
		Res	pectfully submitted,		
Date	d: <u>June 8, 2006</u>	ORI	RICK, HERRINGTON & SUTCHEFE LLP		
ORR	ICK, HERRINGTON & SUTCLIFFE LLP		Reg. No. 39,675		
	k Plaza, Suite 1600 c. CA 92614				

949/567-6700 Telephone 949/567-6710 Facsimile

Approved for use through 7/31/06. OMB 0651-0031
Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE

	Under the Paperwork Reduction Act of 1995, no persons are rec rm 1449A/PTO			quired to respond to a collection of information unless it contains a valid OMB control number of Complete if Known		
			Application Number	10/799529		
	IFORMATION	DISCLOSURI	Ξ.	Filing Date	March 11, 2004	
	TATEMENT BY	ATEMENT BY APPLICANT		First Named Inventor	Podella	
				Art Unit	1636	
	(use as many shee	eets as necessary)	Examiner Name	Akhavan, Ramin		
	1 1	of 1	1	Attorney Docket Number	700145.4004	

U.S. PATENT DOCUMENTS					
Examiner		U.S. Patent Document	Publication Date	. Name of Patentee or	
Initials	Cite No.1	Number-Kind Code ^{2 (I known)}	MM-DD-YYYY	Applicant of Cited Document	
/N.V./	AA	2,320,479	6/19/1939	Sperti	
1	AB	3,404,068	10/1/1968	Battistoni	
\neg	AC	3,635,797	1/18/1972	Battistoni, et al.	
	AD	5,238,925	8/24/1993	Bentley	
	AE	5,356,874	10/18/1994	Bentley	
	AF	5,514,591	5/7/1996	Levin	
\neg	AG	5,714,169	2/3/1998	Levin	
	AH	5,820,758	10/13/1998	Dale, et al.	
\neg	Al	5,849,566	12/15/1998	Dale, et al.	
	AJ	5,885,950	3/23/1999	Daie, et al.	
	AK	5,897,928	4/27/1999	Sanders, et al.	
$\neg \forall$	AL	6.033.875	3/7/2000	Bussineau, et al.	

Sheet

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials'	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the tem (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), youlme-issue number(s), publisher, city and/or country whore goughshade. Baker's Mass Production. Chan & Pages (S14,131,132).	T²		
/N.V./	BA	"Baker's Yeast Production" (Chap. 6, Pages 261-313) 1991			
	BB	William D. Pandolfe, Ph.D., "Cell Disruption by Homogenization"			
	вс	Donna J. Schlemm, et al. "Medicinal Yeast Extracts" Cell Stress and enaperones (February 1999, 4 (3), Pages 171-176)			
	BD	J. Peter Bentley, Ph.D., et al. "Peptides From Live Yeast Cell Derivative Stimulate Wound Healing" Arch Surg (May, 1009, Vol. 124, Pages 641-646) (1.990)			
	BE	Euan W. Low, et al. "Reducing Production of Excess Biomass During Wastewater Treatment" Wat. Res., (Vol. 33, No. 5, pp. 1119-1132, 1999)			
	BF	Euan W. Low, et al. "The Use of Chemical Uncouplers for Reducing Biomass Production During Biodegradation" Wat. Sci. Tech. (Vol. 37, No. 4-5, pp. 399-402, 1998)			
∇	BG	James B. Russell, et al. "Energetics of Bacterial Growth: Balance of Anabolic and Catabolic Reactions" Microbiological Reviews (March, 1995, pp. 48-62)			

Examiner Signature	/Nancy Vogel/	Date Considered	04/09/2007

EXAMNER: Initial if reference considered, whether or not obtain is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered include copy of this form with nost communication to applicant. "Applications usuage colored because the opportunity to prevent the conformation of the prevent of the opportunity by the Moviette order (MPO Standard ST). "Yor Japanese plant indournets," inclination of the year of the regist of the Emportunity plant is obtained by the Standard ST). "Yor Japanese plant indournets," inclination of the year of the regist of the Emportunity plant is obtained and the plant indournets. "Kind of occurrent by the appropriate symbols as indicated on the document under VMPO Standard ST 16 (flossible, /Apoliopiant is to place a check make their Eliaphia in larguage Translation is allowed."

This collection of information is required by 37 CFR. 167 and 1.88. The information is required to obtain or retain a benefit by the public which is to fit quired by the USPTO to process an application. Confidentially a govern by 38 USE 1.22 and 37 CFR. 14. This collection is estimated to black? Brown 30 complete, including galariting interpering, and submitting the considered application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete its form and/or suggesterns for reconsiding bits burders, should be sent to the Chief Information Officer. U.S. Patient and Trademark Office, U.S. Patient Office, U.S. Patient